Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase I/IIa study of NASOX (nal-IRI + S-1 + oxaliplatin) as first-line treatment for pancreatic adenocarcinoma
KCT0005527Phase 2Completed
- Sponsor
- Servier
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, tegafur and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Servier. Started Jun 2021; status: completed.
02
Drugs
nanoliposomal irinotecantegafuroxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on KCT0005527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005527.